US · HLN
Haleon plc
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Weybridge KT13 0NY
- Website
- haleon.com
Price · as of 2025-12-31
$9.38
Market cap 49.3B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $52.90 | +463.97% |
| Intrinsic Value(DCF) | $5.11 | -45.52% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $2.10 | -77.61% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | $0.00 | $8.00 | |||
| 2021 | $2.30 | $1.90 | |||
| 2022 | $7.32 | $34.77 | $0.41 | $0.00 | $6.60 |
| 2023 | $8.33 | $37.85 | $0.00 | $2.20 | $3.60 |
| 2024 | $10.27 | $38.16 | $1.19 | $1.90 | $3.20 |
| 2025 | $10.87 | $39.45 | $1.27 | $0.00 | $2.10 |
AI valuation
Our deep-learning model estimates Haleon plc's (HLN) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $52.90
- Current price
- $9.38
- AI upside
- +463.97%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$5.11
-45.52% upside
Graham-Dodd
—
— upside
Graham Formula
$2.10
-77.61% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| HLN | Haleon plc | $9.38 | 49.3B | +321% | -46% | — | -78% | 22.30 | 2.22 | 3.37 | 15.73 | 178.37 | -3.96 | 64.77% | 22.44% | 15.11% | 10.01% | 7.93% | 4.88% | 0.52 | 7.28 | 0.92 | 0.70 | 2.62 | 1250.00% | -396.00% | -391.00% | 5.42% | 0.46 | 8.27% | 1.65% | 36.70% | 5.15% | 18.02 | 22.14 | 4.04 | 3.11 |
| A | Agilent Technologies, Inc… | $121.38 | 34.41B | -21% | -48% | -87% | -44% | 96.67 | 6.22 | 6.04 | 23.72 | 3059.02 | 23.01 | 52.43% | 21.29% | 18.75% | 6.87% | 16.33% | 3.53% | 0.50 | 13.21 | 1.96 | 1.40 | 0.85 | 316.00% | 673.00% | -1610.00% | 2.75% | 0.66 | 14.01% | 0.67% | 65.00% | 3.31% | 29.43 | 37.78 | 6.26 | 5.50 |
| ALC | Alcon Inc. | $87.18 | 42.49B | -32% | -61% | -65% | -71% | 42.77 | 1.90 | 4.03 | 19.38 | — | 11.11 | 55.24% | 13.08% | 9.42% | 4.50% | 4.55% | 3.17% | 0.24 | — | 2.12 | 1.16 | 1.58 | -341.00% | 494.00% | 2281.00% | 4.12% | 0.74 | 6.84% | 0.40% | 16.90% | 2.12% | 33.49 | 26.36 | 4.38 | 3.24 |
| BDX | Becton, Dickinson and Com… | $176.48 | 63.94B | +10% | -66% | — | -47% | 25.90 | 1.71 | 1.99 | 12.47 | — | -4.09 | 45.44% | 11.80% | 7.68% | 6.54% | 5.17% | 2.98% | 0.76 | 4.21 | 1.11 | 0.46 | 3.70 | -51.00% | 823.00% | -1309.00% | 6.14% | 0.41 | 6.01% | 2.75% | 71.30% | 8.27% | 23.97 | 23.14 | 2.83 | 1.86 |
| CAH | Cardinal Health, Inc. | $229.23 | 53.94B | -51% | +121% | — | -82% | 22.84 | -12.89 | 0.16 | 13.30 | 26.27 | -2.40 | 3.67% | 1.02% | 0.70% | -52.35% | -7229.54% | 3.19% | -3.36 | 10.58 | 0.94 | 0.44 | 1.76 | 8696.00% | -187.00% | -4309.00% | 5.16% | 0.06 | -7872.34% | 1.38% | 31.50% | 3.51% | 18.16 | 22.33 | 0.19 | 4.68 |
| HUM | Humana Inc. | $190.54 | 22.92B | -18% | +504% | -67% | -8% | 18.99 | 1.28 | 0.17 | 5.17 | — | 2.83 | 14.54% | 1.12% | 0.92% | 6.98% | 6.79% | 2.49% | 0.70 | 2.30 | 2.00 | 1.42 | 2.81 | -140.00% | 1006.00% | -8432.00% | 1.66% | 0.06 | 2.12% | 1.91% | 36.20% | 5.92% | 10.34 | 40.07 | 0.12 | 4.42 |
| INSM | Insmed Incorporated | $149.33 | 31.85B | -50% | +3,425% | — | — | -24.48 | 42.30 | 51.55 | -26.12 | -162.35 | 61.87 | 79.41% | -194.04% | -210.54% | -249.28% | -969.45% | -59.53% | 1.04 | -14.04 | 3.83 | 3.35 | -0.22 | 1508.00% | 6673.00% | 3709.00% | -3.10% | -1.99 | -797.14% | 0.00% | 0.00% | 1.60% | -26.00 | -31.62 | 50.46 | 8.06 |
| IQV | IQVIA Holdings Inc. | $178.81 | 30.45B | -2% | -53% | — | -39% | 22.01 | 4.61 | 1.84 | 12.70 | 471.04 | -1.99 | 26.28% | 14.02% | 8.34% | 21.65% | 9.92% | 4.79% | 2.49 | 3.14 | 0.75 | 0.67 | 4.10 | 467.00% | 587.00% | -298.00% | 6.85% | 0.32 | 10.54% | 0.00% | 0.00% | 4.15% | 19.23 | 21.45 | 2.70 | 1.83 |
| RMD | ResMed Inc. | $256.26 | 37.41B | -10% | -40% | -86% | -35% | 28.88 | 6.78 | 7.86 | 20.96 | 77.17 | 16.47 | 59.36% | 32.75% | 27.22% | 25.86% | 25.33% | 18.62% | 0.14 | 133.66 | 3.44 | 2.16 | -0.19 | 3743.00% | 984.00% | 2918.00% | 4.11% | 1.72 | 29.91% | 0.77% | 22.20% | 3.96% | 23.79 | 24.13 | 7.79 | 13.72 |
| TAK | Takeda Pharmaceutical Com… | $18.75 | 59.23B | +21% | -68% | — | -82% | 66.53 | 1.04 | 1.57 | 9.33 | — | -3.55 | 65.51% | 7.48% | 2.36% | 1.52% | 1.87% | 0.74% | 0.65 | 2.49 | 1.01 | 0.45 | 3.41 | -2624.00% | 745.00% | 26347.00% | 11.93% | 0.42 | 7.55% | 4.21% | 280.30% | 8.50% | 32.96 | 13.18 | 2.46 | 1.11 |
| ZTS | Zoetis Inc. | $131.10 | 57.77B | -7% | -40% | -99% | -53% | 21.39 | 17.17 | 6.04 | 15.82 | 212.77 | -131.77 | 70.49% | 38.00% | 28.23% | 65.99% | 28.56% | 18.00% | 2.85 | 14.80 | 3.03 | 1.75 | 1.76 | 1005.00% | 228.00% | -65.00% | 3.99% | 1.30 | 22.78% | 1.55% | 33.30% | 7.21% | 17.89 | 28.19 | 6.80 | 5.80 |
About Haleon plc
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.
- CEO
- Brian James McNamara
- Employees
- 24.56K
- Beta
- 0.19
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($5.11 ÷ $9.38) − 1 = -45.52% (DCF, example).